Core Insights - Tempus AI (TEM) is enhancing its leadership in precision medicine through impactful research initiatives and clinical validations, particularly in AI-driven diagnostics for cancer treatment decisions [1] Research and Clinical Validation - In January 2026, TEM's Immune Profile Score (IPS) was shown to more accurately predict outcomes for patients receiving immune checkpoint inhibitors (ICIs) compared to conventional biomarkers like tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1 [2] - A study published in September 2025 in JCO Precision Oncology validated the clinical utility of the PurIST algorithmic diagnostic, providing the largest real-world evidence to date for guiding first-line treatment decisions in advanced pancreatic ductal adenocarcinoma (PDAC) [3] - In April 2025, TEM published a study in the Journal of Molecular Diagnostics supporting the xF+ non-invasive technique for detecting actionable variants, identifying clinically relevant biomarkers, and monitoring disease progression [4] Peer Updates - Illumina (ILMN) reported in November 2025 that whole-genome sequencing (WGS) reveals more about the genetic causes of common diseases than older methods, with rare variants identified through WGS accounting for much of the missing heritability in complex diseases [5] - Myriad Genetics (MYGN) presented new data at the 2026 ASCO-GU conference supporting its various cancer tests, highlighting its expanding role in cancer care [6] Stock Performance - Over the past year, Tempus' shares have increased by 15.8%, contrasting with a 25.3% decline in the industry, while the S&P 500 composite has improved by 24.2% [7] Valuation Metrics - TEM currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 5.67X, compared to the industry median of 5.34X, indicating an expensive valuation [10] - The loss per share estimate for 2025 has widened from 42 cents to 56 cents over the past 30 days [11]